The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

The present invention relates to a novel polymeric composition comprising a novel polymer having two or more repeat units and a terminus having the structure (1): wherein R1 represents a C1-C20 substituted or unsubstituted alkyl group, w is a number from 1-8, X is oxygen (O) or nitrogen (N), and Rd is a reactive group. The invention also relates to a process for forming a pattern using the novel polymeric composition. The invention further relates to a process of making the novel polymer.

Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecu le, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.

The present invention relates to lithium salt-containing rare earth halide solutions in aprotic solvents, processes for production thereof and also use thereof.

Methods and compositions for the deposition of a film on a substrate. In general, the disclosed compositions and methods utilize a precursor containing calcium or strontium.

Substrates for detecting microorganisms are provided, wherein the substrate comprises a set of molecular markers linked, optionally with linker molecules or moieties, to a di-, or tripeptide consisting of amino acids X1 and X2, or X1, X2 and X3, in which one of them, for example, X1, is a D-amino acid and the others, for example, X2 and X3, may be any D- or L-amino acid. The substrate preferably is used for the detection of Bacillus anthracis. Also provided are substrates for detecting Pseudomonas aeruginosa, wherein the substrate comprises a set of molecular markers linked, optionally with linker molecules or moieties to a tri-, tetra-, or pentapeptide consisting of glycine amino acids. The invention further comprises methods for detecting microorganisms, specifically B. anthracis and P. aeruginosa, with the substrates of the invention and use of the substrate(s) in such a method.

The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.

The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity.

A light absorption anisotropic film, wherein content of a liquid crystalline non-colorable low molecular weight compound is 30% by mass or less; and which is obtained by fixing the alignment of a dichroic dye composition comprising at least one type of azo-based dichroic dye having nematic liquid crystallinity; and shows a diffraction peak derived from a periodic structure in a direction parallel to the alignment axis on measurement of X-ray diffraction. The light absorption anisotropic film is high in dichroism.

The present invention relates to an (amide amino alkane) metal compound represented by the formula (1): wherein M represents a metal atom;R1 represents a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms;R2 and R3 may be the same as, or different from each other, and each independently represents a linear or branched alkyl group having 1 to 3 carbon atoms, or R2 and R3 may form a substituted or unsubstituted 5- or 6-membered ring together with the nitrogen atom to which they are bound;Z represents a linear or branched alkylene group having 1 to 10 carbon atoms (a part of which may optionally form a ring); andn represents a number of the ligands, which is equal to the valence of the metal (M), and represents an integer of from 1 to 3; with the proviso that the metal compounds in which M is Li (Lithium), Be (Beryllium), Ge (Germanium) or Nd (Neodymium) are excluded;the metal compounds in which M is Mg (Magnesium) and R1 is methyl group are excluded;the metal compounds in which M is Zn (Zinc) and R1 is methyl group are excluded;the metal compounds in which M is Bi (Bismuth) and R1 is t-butyl group are excluded; andin cases where n is two or greater, two or more ligands may be the same as, or different from each other; and a method of producing a metal-containing thin film using the metal compound.

A method for making diazo-compounds, diazonium salts thereof and other protected forms of these compounds. Diazo-compounds are prepared by reaction of a tertiary phosphine reagent carrying a reactive carbonyl group with an azide. The reaction can also generate an acyl triazene which can be converted thermally or by addition of base to form the diazo-compound or the acyl triazene can be isolated. The method is particularly useful for conversion of azides carrying one or more electron withdrawing groups to diazo-compounds. The method can be carried out in aqueous medium under mild conditions and is particularly useful for conversion of azido sugars to diazo-compounds and diazonium salts thereof under physiological conditions. Tertiary phosphine reagents, particularly those that are water-soluble, and precursors for preparation of the reagents are provided.

A cycloalkyl triamine pentacarboxylate compound coordinating to a metal ion to form a high stability metal complex in serum is provided. The metal complex of the present invention can be used as a contrast agent for magnetic resonance imaging (MRI).

Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA-IX, and a radionuclide adapted for radioimaging and/or radiotherapy:

This invention relates to novel Ln(III) complexes of pybox, and methods of making the same. The present invention also relates to a method of use of pybox as a chelating moiety and sensitizer for Ln(III) ion luminescence. Derivatives of pybox and methods of making the same are also provided.

Disclosed is a spectrofluorimetrically detectable luminescent composition consisting essentially of at least one energy transfer acceptor lanthanide(III) complex having an emission spectrum maximum in the range from 300 to 2000 nanometers and a luminescence-enhancing amount of at least one energy transfer donor selected from the group consisting of a fluorophore, a lumiphore, an organic compound, a salt of an organic ion, a metal ion, a metal ion complex, or a combination thereof. Such energy transfer donor enhances the luminescence of at least one energy transfer acceptor lanthanide(III) complex, with the conditions that the emission spectrum of any energy transfer donor differs from that of its energy transfer acceptor lanthanide(III) complex; and such energy transfer donor can be dissolved to form a unitary solution in a solvent having an evaporation rate at least as great as that of water.

The invention relates to basic bisazo compounds according to formula (I) wherein all substituents are defined as in Claim 1, their production, their use as dyestuffs as well as material dyed with these dyestuffs.

A light absorption anisotropic film, having at least one dichroic dye, in which the light absorption anisotropic film shows a diffraction peak derived from a periodic structure in a direction in a plane of the light absorption anisotropic film in X-ray diffraction measurement and the diffraction peak has a half width of 1.0 Å or less.

A coloring matter which exhibits excellent (ozone) gas resistance, high print density, low color rendering properties, low color saturation, and high-quality black hue when is recorded on a paper only for inkjet exclusive use, i.e., an azo compound represented by formula (1), a tautomer of the azo compound, or a salt of the azo compound or the tautomer; and an ink composition containing the coloring matter, particularly a black ink composition for inkjet recording applications.

The new metal azo pigments comprising the adduct of a) at least two metal azo compounds of the formula (I) or their tautomeric forms in which the substituents have the definition indicated in the description,and b) at least one compound of the formula (II) in whichR6 has the definition indicated in the description, are characterized in that in the X-ray diffractogram with a lattice constant of d=10.3 (±0.2) Å the metal azo pigment has a signal S1 with an intensity I1 and in the lattice constant range from d=16.05 Å to d=11.78 Å has no signal S2 whose intensity I2 in relation to the intensity I1 of signal S1, expressed as ratio I2/I1 of the background-corrected intensities, exceeds a value of 0.02,and are outstandingly suitable for producing pigment preparations and especially for producing color filters.

It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.

Disclosed is a process for preparing a polyester or copolymer containing ester functionalities. The process can comprise: providing an optionally substituted lactone having a ring size of from 6 to 40 carbon atoms; andsubjecting said lactone to metal mediated ring-opening polymerization using as catalyst a compound according to general formula (I): wherein M can be Al, Cr, Mn and Co;X and X' are independently a heteroatom;Y and Y' can be, independently, selected from O, N, S, P, C, Si, and B;Z can be selected from hydrogen, borohydrides, aluminum hydrides, carbyls, silyls, hydroxide, alkoxides, aryloxides, carboxylates, carbonates, carbamates, amidos, thiolates, phosphides, and halides;L1 and L2 can be independently an organic ligand linking X and Y together and linking X' and Y' together, respectively; andL3 is an optional organic ligand linking Y and Y' together.

The purpose of the present invention is to provide novel liquid crystalline compounds that are capable of inducing phase transition by a light stimulus and are useful in the display, optoelectronics, and photonics field. The present invention relates to the liquid crystalline compounds represented by general formula (1): wherein R1, R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, alkoxyl, alkoxycarbonyl, alkoxycarbonyloxy, alkanoyl, alkanoyloxy, alkoxyphenyl, and N-alkylaminocarbonyl, and n is an integer.

The present invention relates to a 68Ga generator, wherein the 68Ge parent nuclide thereof is attached specifically to a support through a triethoxyphenyl group and continuously disintegrates to 68Ga, the triethoxyphenyl group being covalently bound to a support material through a linker.

Disclosed is an azo compound represented by the formula (1) below, a salt thereof, or a copper complex salt compound thereof. (In the formula, R1 and R2 independently represent a hydrogen atom, a sulfonic acid group, a lower alkyl group or a lower alkoxyl group; R3-R6 independently represent a hydrogen atom, a lower alkyl group or a lower alkoxyl group; R7 represents a lower alkyl group or a lower alkoxyl group; and n represents 0 or 1.)

Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.

A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another molecule having affinity for said ligand, to c) an effector agent, optionally via a linker 2, said effector agent exerting its effect on cells, tissues and/or humorous molecules in vivo or ex vivo, and to d) a biomolecule reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomolecule.

This invention relates to bis-azo colorants for use as bluing agents, laundry care compositions comprising bis-azo colorants that may serve as bluing agents, processes for making such bluing agents and laundry care compositions and methods of using the same. The bluing agents are generally comprised of at least two components: at least one chromophore component and at least one polymeric component. These bluing agents are advantageous in providing a whitening effect to fabrics, while not building up over time and causing undesirable blue discoloration to the treated fabrics.

Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include thioureas, diphenyldiazerenes, xanthenes, and isoindoles and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.

The present invention relates to compounds suitable as modulators of protein misfolding and/or protein aggregation. The compounds are particularly suitable as inhibitors of amyloid aggregate formation and/or modulators of amyloid surface properties, and/or as activators of degradation or reduction of amyloid aggregates.

The rare-earth complex of the present invention has high luminous efficiency, since it has a structure represented by the following general formula (I):

Provided, amongst other things, are dyes of formula II: wherein R1, R2, R3 and R4 are independently H or alkyl, so long as one or more is alkyl, and salts of the compound of formula II. Methods of making, inks, surgical markers and methods of marking tissue and the like are further provided.

The present invention concerns a Ga68 complex of formula FOLATE-(LINKER)i-NOTA-Ga68 in which: 1) FOLATE is a folate compound or a derivative thereof capable of targeting a folate receptor,2) NOTA is a chelate capable of complexing Ga68 having a NOTA scaffold or derivatives thereof3) LINKER is a chemical group linking FOLATE and NOTA4) i is an integer chosen between 0 and 1 wherein NOTA is complexing Ga68.

Disclosed herein is a GO-Gd-DTPA (gadolinium-diethylenetriamine pentaacetic-graphene oxide) complex, which is formed by an ester bond of graphene oxide (GO) and gadopentetic acid (Gd-DTPA). Since the GO-Gd-DTPA can stably exist in the body because it has high stability in water, it is expected that it can be effectively used as an MRI contrast agent.

The present disclosure provides a photoreactive synthetic regulator of protein function. The present disclosure further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present disclosure further provides methods of modulating protein function, involving use of light.

The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

An organic compound has the following chemical structure: wherein R is different from R*; R and R* are independently hydrogen, halogen, nitro or methoxyl; and R1 is a C1-C6 alkyl or a phenyl group. A quaternary data storage device includes a bottom electrode, a top electrode, and the organic film layer sandwiched between the bottom electrode and the top electrode.

A liquid-crystal compound denoted by general formula (I) below wherein each of the groups is defined and Dye denotes an azo dye residue denoted by general formula (II) with X and n also being defined. The azo liquid-crystal compound is capable of orientation with a high degree of orientation order.

Porphyrin compounds are provided. The compounds may further comprise a fused polycyclic aromatic hydrocarbon or a fused heterocyclic aromatic. Fused polycyclic aromatic hydrocarbon s and fused heterocyclic aromatics may extend and broaden absorption, and modify the solubility, crystallinity, and film-forming properties of the porphyrin compounds. Additionally, devices comprising porphyrin compounds are also provided. The porphyrin compounds may be used in a donor/acceptor configuration with compounds, such as C60.

Provided is an oligonucleotide containing an azobenzene derivative, represented by Formula (1) or (2) below: (in the formulae, A1 and A2 each independently represent a hydrogen atom, nucleotide or oligonucleotide, B1 and B2 each independently represent a hydroxyl group, nucleotide or oligonucleotide, R11 and R12 each independently represent a C1-20 alkyl group, R21 and R22 each independently represent a hydrogen atom or C1-20 alkyl group, and R13 to R18 and R23 to R28 each independently represent a hydrogen atom; a C1-20 alkyl group or alkoxy group optionally substituted with a halogen atom, hydroxyl group, amino group, nitro group or carboxyl group; a C2-20 alkenyl group or alkynyl group optionally substituted with a halogen atom, hydroxyl group, amino group, nitro group or carboxyl group; a hydroxyl group; a halogen atom; an amino group; a nitro group; or a carboxyl group).

The present invention provides a family of dark quenchers, termed Black Hole Quenchers (“BHQs”), that are efficient quenchers of excited state energy but which are themselves substantially non-fluorescent. Also provided are methods of using the BHQs, probes incorporating the BHQs and methods of using the probes.

The present disclosure relates to an azoquinone compound represented by formula (1) below. In formula (1), R1 to R4 are identical or different and each represents a hydrogen atom, a C1 to C6 alkyl group or a C6 to C12 aryl group, and Ar represents a C6 to C12 aryl group.

Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of cancer.

A hypoxia contrast medium including nitroimidazole-amino acid chelate with a positively charged radioactive nuclide, a preparation method and use thereof. The contrast medium can be used in imaging cerebral thrombosis, tumors or other diseases such as ulceration, thrombosis, and so on.

The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.

A location aware user interface on a wireless handset is described. The location aware user interface comprises a location module configured to transmit a location message to a remote server via a network. The remote server is configured to determine whether the wireless handset is within a geofence. The user interface further comprises a display module configured to display at least one content item associated with the geofence. The user interface also comprises an input module configured to receive a user-created content item and transmit the received user-created content item to the remote server. The remote server is configured to associate the content item with the geofence in which the wireless handset is located.

Monitoring user activity on a mobile device is described. In one aspect, video content is received and played to a user of the mobile device. The monitoring activity detects an interruption of playback of the video content and determines an event associated with the interruption. The event is stored in the mobile device and communicated to a remote device.

A system that incorporates teachings of the present disclosure may include, for example, a set top box (STB) comprising a controller programmed to receive measurement data stored in a first wireless device serving as a portable monitoring gateway that collects subscriber collected data and store and analyze the measurement data at the STB using the received measurement data received from the first wireless device and optionally from a remote server or a local storage space having stored measurement data to provide analyzed results. Other embodiments are disclosed.

A system or method for inferring and selective display of visual and sound media content based on a pet(s)'s level of engagement or reactions to content displayed on any number of content display devices including, but not limited to, television screens, computer monitors, tablets, and cell phones and measured by a sensor. A content selection algorithm takes as input the sensor measurements and historical or pre-computed data to infer the pet(s)'s preference for content. A content modification algorithm interposes algorithmically computed shapes and sounds overlaid on top of the existing content to attract the attention of the pet(s) observing the display.

This broadcasting receiver includes a receiving portion receiving a broadcast signal, a determination portion determining whether or not a user to be subject to parental control of the broadcast signal has entered a prescribed range, and a control portion performing control of enabling parental control corresponding to a user determined to have entered the prescribed range in the case where the parental control corresponding to the user determined to have entered the prescribed range is disabled when the determination portion determines that the user to be subject to parental control has entered the prescribed range.